

GRADE/DECIDE meeting

Status report on the DECIDE project



Five empirical workpackages and one to package results

- Health professionals (WP1)
- Policymakers and managers (WP2)
- Public, patients and carers (WP3)
- Diagnostic tests (WP4)
- Health systems policies (WP5)


- Tools to support guideline development (WP6)




Now at the start of Year 5, the last year

- Evidence to Decision (EtD) frameworks (all WPs)
- Interactive Summary of Findings tables (all WPs)
- Shared decision-making tools (WPs 1 and 3)
- Update of the GIN Public Toolkit chapter for developing patient versions of guidelines (WP3)
- The GET IT glossary (all WPs)
- GRADEPro Guideline Development Tool (WP6)






DECIDE **iEtD framework and iSoF**



The DECIDE project has received funding from the European Community's Seventh Framework Programme under Grant Agreement no. 258583

GRADE/DECIDE - 5/3/2015

DECIDE **iEtD framework and iSoF**



The DECIDE project has received funding from the European Community's Seventh Framework Programme under Grant Agreement no. 258583


GRADE/DECIDE - 5/3/2015

Collaboration with



<http://www.magicproject.org>







G-I-N PUBLIC Toolkit:
*Patient and Public
Involvement in
Guidelines*

**Aims to support
guideline developers
considering involving
patients in guideline
development or
dissemination**

Patient versions of guidelines

What will

- If you need to improve your oral hygiene, your dentist will show you the best way to do this and also help you plan when to brush and floss.
- If you have periodontitis, your dentist will show you how to improve your oral hygiene and how to remove the build-up of plaque. You may need intensive treatment.
- If you smoke, your dentist will advise you to stop.
- If you have diabetes, your dentist will advise you to keep your blood sugar well-controlled, as this will help to prevent developing gum disease.

Why has t

SDCEP has recently provided guidance on how to prevent and treat gum disease. This guidance is based on the advice of clinical experts, researchers and patients. It will make a difference to the health of many people.

Why have I been given this leaflet?

You may have told the dentist that you taste and see blood when you clean your teeth, or that you feel that some of your teeth may be loose. Your dentist may have noticed that your gums bleed or that you need to improve your oral hygiene. Bleeding is a sign of gum disease.

What is gum disease?

Gum disease, also known as periodontal disease, is caused by a build up of plaque on the teeth. If plaque is not regularly removed by brushing, the gums can become irritated and inflamed. Plaque which is not removed eventually hardens into a substance called calculus which is also irritating to the gums. Calculus has to be removed by your dentist or hygienist.

Gingivitis

The early stage of gum disease is called gingivitis. The symptoms are swollen, red gums which bleed easily when you brush, floss or eat hard foods, such as apples. You may also notice an unpleasant or metallic taste in your mouth. A relative or friend may complain that you have bad breath. Gingivitis is reversible with good oral hygiene.

Periodontitis

If gingivitis is left untreated, it can develop into a more advanced stage of periodontal disease called periodontitis. If left untreated, periodontitis can lead to receding gums, loose teeth and eventual tooth loss.

Can I prevent gum disease?

Most people can prevent gum disease with good oral hygiene. The table lists some key things you can do to improve your oral hygiene and prevent gum disease.

Recommendation 1

Brush your teeth regularly and effectively

Improving your oral hygiene reverses the early stages of gum disease. Your dentist or hygienist can help by showing you how to brush your teeth in the most effective way.

Recommendation 2

Have a plan of when you will brush your teeth

Having a firm plan will help you remember to brush your teeth. For example, you could plan to always brush first thing in the morning when you get up and last thing at night when getting ready for bed.

Recommendation 3

Use an ordinary toothbrush or a rechargeable powered toothbrush and fluoride toothpaste

Rechargeable powered toothbrushes may remove more plaque than ordinary toothbrushes. However, both types of toothbrush are good for removing plaque if they are used properly.

What else can I do?

- **Stop smoking**
- **Clean between your teeth using floss or interdental brushes**

Flossing in addition to toothbrushing may make gums less likely to bleed. Using interdental brushes in addition to toothbrushing may remove even more plaque.



The glossary is specifically intended to be useful to people without a research background, particularly those wanting to make an informed choice about a treatment.

It is also aimed at those communicating research evidence to the general public, or teaching others about how to assess claims made about treatments.



bias

“A type of error that may affect the results of a [study](#) because of weaknesses in its design, analysis or reporting”

Synonyms:

systematic error

Plain language suggested term:

bias

Full explanation:

Biases (systematic errors) distort [effect estimates](#) away from the actual effect. Biases are caused by inadequacies in the design, conduct, analysis, reporting or interpretation of [treatment comparisons](#). Because it is generally not possible to know the degree to which an effect estimate is biased, judgements must be made about the [risk of bias](#) using criteria that assess factors that are known or thought to be associated with bias, such as unconcealed [allocation](#) of [participants](#) to treatments (see [allocation schedule concealment](#)). In everyday language, bias has other meanings, for example “prejudice”.

See also:

[allocation bias](#) · [confirmation bias](#) · [disease progression bias](#) · [lead-time bias](#) · [measurement bias](#) · [performance bias](#) · [random error](#) · [reporting bias](#) · [risk of bias](#);



Login



it's **FREE**

Create bookmark
to launch offline

A new version of **GRADEpro** proudly engineered by:



Evidence Prime
The tools for health care decisions

The official tool of



and



gdt.guidelinedevelopment.org

GRADE

AI vs tamoxifen

streweek@mac.com

Should aromatase inhibitor monotherapy vs. tamoxifen be used in postmenopausal women with oestrogen sensitive ear

Explanations

Help

TASKS

TEAM

SCOPE

DOCUMENT SECTIONS

COMPARISONS

OUTCOMES

SEARCHING

SCREENING

DATA EXTRACTION

RISK OF BIAS

ANALYSES

EVIDENCE TABLE

RECOMMENDATIONS

DISSEMINATION

CRITERIA	JUDGEMENTS	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS															
Is there a problem priority?	<input type="radio"/> No <input type="radio"/> Probably no <input type="radio"/> Uncertain <input type="radio"/> Probably yes <input type="radio"/> Yes <input type="radio"/> Varies																	
What is the overall certainty of this evidence?	<input type="radio"/> No included studies <input type="radio"/> Very low <input type="radio"/> Low <input type="radio"/> Moderate <input type="radio"/> High	The relative importance or values of the main outcomes of interest: <table> <thead> <tr> <th>Outcome</th> <th>Relative importance</th> <th>Certainty of the evidence (GRADE)</th> </tr> </thead> <tbody> <tr> <td>disease free survival</td> <td>CRITICAL</td> <td>++++ HIGH</td> </tr> <tr> <td>overall survival</td> <td>CRITICAL</td> <td>+++ MODERATE</td> </tr> <tr> <td>Fracture</td> <td>IMPORTANT</td> <td>++++ HIGH</td> </tr> <tr> <td>cardiovascular disease</td> <td>IMPORTANT</td> <td>++++ HIGH</td> </tr> </tbody> </table>	Outcome	Relative importance	Certainty of the evidence (GRADE)	disease free survival	CRITICAL	++++ HIGH	overall survival	CRITICAL	+++ MODERATE	Fracture	IMPORTANT	++++ HIGH	cardiovascular disease	IMPORTANT	++++ HIGH	
Outcome	Relative importance	Certainty of the evidence (GRADE)																
disease free survival	CRITICAL	++++ HIGH																
overall survival	CRITICAL	+++ MODERATE																
Fracture	IMPORTANT	++++ HIGH																
cardiovascular disease	IMPORTANT	++++ HIGH																
Is there important uncertainty about how much people value the main outcomes?	<input type="radio"/> Important uncertainty or variability <input type="radio"/> Possibly important uncertainty or variability <input type="radio"/> Probably no important uncertainty of variability <input type="radio"/> No important uncertainty of variability <input type="radio"/> No known undesirable	Summary of findings: tamoxifen <table> <thead> <tr> <th>Outcome</th> <th>Without aromatase inhibitor monotherapy</th> <th>With aromatase inhibitor monotherapy</th> <th>Difference (95% CI)</th> <th>Relative effect (RR) (95% CI)</th> </tr> </thead> <tbody> <tr> <td></td> <td>109 per 1000</td> <td>98 per 1000 (92 to 105)</td> <td>11 fewer per 1000 (from 4 fewer to 18 fewer)</td> <td></td> </tr> <tr> <td>disease free survival</td> <td>107 per 1000</td> <td>96 per 1000 (89 to 103)</td> <td>11 fewer per 1000 (from 4 fewer to 18 fewer)</td> <td>HR 0.89 (0.83 to 0.95)</td> </tr> </tbody> </table>	Outcome	Without aromatase inhibitor monotherapy	With aromatase inhibitor monotherapy	Difference (95% CI)	Relative effect (RR) (95% CI)		109 per 1000	98 per 1000 (92 to 105)	11 fewer per 1000 (from 4 fewer to 18 fewer)		disease free survival	107 per 1000	96 per 1000 (89 to 103)	11 fewer per 1000 (from 4 fewer to 18 fewer)	HR 0.89 (0.83 to 0.95)	
Outcome	Without aromatase inhibitor monotherapy	With aromatase inhibitor monotherapy	Difference (95% CI)	Relative effect (RR) (95% CI)														
	109 per 1000	98 per 1000 (92 to 105)	11 fewer per 1000 (from 4 fewer to 18 fewer)															
disease free survival	107 per 1000	96 per 1000 (89 to 103)	11 fewer per 1000 (from 4 fewer to 18 fewer)	HR 0.89 (0.83 to 0.95)														
Are the desirable anticipated effects large?	<input type="radio"/> No <input type="radio"/> Probably no <input type="radio"/> Uncertain <input type="radio"/> Probably yes <input type="radio"/> Yes <input type="radio"/> Varies																	

- Background papers on guideline methodologies specific to medical testing
- Multilayered presentation formats for guidelines
- PLoS Medicine series on EtDs (submitted)
- Survey of producers' patient versions of guidelines (submitted)
- Survey of presenting continuous outcomes (submitted)
- Focus group work with patients and journalists (in prep)
- Interviews with guideline developers for medical tests (in prep)
- The DECIDE conference, GIN, HTAi, Cochrane



- Background papers on guideline methodologies specific to



Journal of Clinical Epidemiology 67 (2014) 760–768

**Journal of
Clinical
Epidemiology**

Applying Grading of Recommendations Assessment, Development and Evaluation (GRADE) to diagnostic tests was challenging but doable[☆]

Gowri Gopalakrishna^{a,*}, Reem A. Mustafa^{b,c,d}, Clare Davenport^e, Rob J.P.M. Scholten^f,
Christopher Hyde^g, Jan Brozek^{b,c}, Holger J. Schünemann^{b,c}, Patrick M.M. Bossuyt^a,
Mariska M.G. Leeftang^a, Miranda W. Langendam^a

^aDepartment of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, University of Amsterdam, PO Box 22700, 1100 DE Amsterdam, The Netherlands



- Background papers on guideline methodologies specific to medical testing
- Multilayered presentation formats for guidelines
- PLoS Medicine series on EtDs (submitted)
- Survey of producers' patient versions of guidelines (submitted)
- Survey of presenting continuous outcomes (submitted)
- Focus group work with patients and journalists (in prep)
- Interviews with guideline developers for medical tests (in prep)
- The DECIDE conference, GIN, HTAi, Cochrane



Five groups

- **Group 1:** GRADEPro GDT
- **Group 2:** iEtD frameworks and iSoFs
- **Group 3:** Patient versions of guidelines
- **Group 4:** The GET IT glossary
- **Group 5:** Types of recommendations

